INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 1 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,957,600 | – | 2,000,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Context Capital Management, LLC | 2,500,000 | $2,486,000 | 1.44% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 20,000,000 | $19,894,000 | 1.32% |
| SSI INVESTMENT MANAGEMENT LLC | 6,154,000 | $6,089,000 | 0.45% |
| CSS LLC/IL | 7,750,000 | $7,713,000 | 0.44% |
| Senvest Management, LLC | 5,000,000 | $4,998,000 | 0.44% |
| Antara Capital LP | 2,000,000 | $1,989,000 | 0.43% |
| LINDEN ADVISORS LP | 28,527,000 | $28,380,000 | 0.43% |
| Graham Capital Management, L.P. | 10,650,000 | $10,579,000 | 0.31% |
| WOLVERINE ASSET MANAGEMENT LLC | 19,000,000 | $18,904,000 | 0.25% |
| Polar Asset Management Partners Inc. | 10,000,000 | $9,957,000 | 0.18% |